DiabloWags said:
NATERA Q1 EARNINGS SOLID.
Revenues $501.8 million vs $367.7 million
37% YoY product growth.
63.1% gross margins.
25 Presentations coming up at ASCO - May 30 - June 3 in Chicago
Genentech Trial readout due at midyear in bladder cancer.
This would be the first companion DX test.
1.0 Million 22q tests (Di George Syndrome) performed with no reimbursement.
It's built into the COGS, the CPT code is already in place (@$750) and once in guidelines this will really be a big boost to revs. Could be anywhere between $200 - $500 reimbursement per test.
Do the Math.
45% of oncologists are already placing orders for Signatera (ctDNA)
Natera, Inc. | Natera Reports First Quarter 2025 Financial Results
Another earnings with negative EPS. When will they break even?